Literature DB >> 9634788

Antibody VH domains as small recognition units.

J Davies1, L Riechmann.   

Abstract

To develop immunoglobulin based recognition units of minimum size, a human heavy chain variable domain (VH) was designed for selection of phage displayed VH. Non-specific binding of the VH through its interface for the light chain variable domain (VL) was prevented through three mutations (G44E, L45R and W47G) in this interface. These mutations were introduced to mimic camelid antibody heavy chains naturally devoid of light chain partners. The third hypervariable loop of the modified VH was then randomised to yield a repertoire of 2 x 10(8) independent clones, which was displayed on phage and selected through antigen binding. VH clones specific for hapten and protein antigens were isolated. Soluble VH was expressed with an isoleucine residue at position 47 to improve expression and stability compared to VH containing a glycine residue at this position, which however was preferable for phage selection. Affinities of soluble VH for hapten were between 100 nM and 400 nM. The VH domains were highly specific, stable and well expressed in Escherichia coli. These positive biophysical properties and their small size make them attractive for biotechnological applications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9634788     DOI: 10.1038/nbt0595-475

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  22 in total

1.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

2.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

Authors:  M Lauwereys; M Arbabi Ghahroudi; A Desmyter; J Kinne; W Hölzer; E De Genst; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

Review 3.  Bispecific antibodies in cancer immunotherapy.

Authors:  Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal:  Hum Vaccin Immunother       Date:  2016-06-01       Impact factor: 3.452

4.  Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold.

Authors:  G Beste; F S Schmidt; T Stibora; A Skerra
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire.

Authors:  V K Nguyen; R Hamers; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

Review 6.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.

Authors:  Weizao Chen; Rui Gong; Tianlei Ying; Ponraj Prabakaran; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Curr Drug Discov Technol       Date:  2014-03

8.  Backbone assignment, secondary structure and protein A binding of an isolated, human antibody VH domain.

Authors:  L Riechmann; J Davies
Journal:  J Biomol NMR       Date:  1995-09       Impact factor: 2.835

Review 9.  Nanobodies in cancer.

Authors:  Elisha R Verhaar; Andrew W Woodham; Hidde L Ploegh
Journal:  Semin Immunol       Date:  2020-11-30       Impact factor: 11.130

Review 10.  Discovery of Antivirals Using Phage Display.

Authors:  Esen Sokullu; Marie-Soleil Gauthier; Benoit Coulombe
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.